In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

ESC registries, Organised by EURObservational Research Programme

ESC Congress Report

Learn more about EORPThe EURObservational Research Programme started  5 years ago when the ESC Board recognized the need to produce good, robust European data on how cardiology is practised in Europe. We thought that this was our duty towards the ESC NCSs, the European agency and authorities and the only practical way to understand whether guidelines are implemented. The programme has 5 goals:

  • To be truly representative  of European cardiology and this has been achieved by allowing a fixed numbers of centres according to the population of each country and a fixed number of hospitals or institutions dealing with the different complexities;
  • To be conducted at the EHH, and today we are proud to announce that we have a group of 12 people extremely professional who are dealing with data monitoring, data entry and data cleaning and we can count on 11 monitors;
  • To cooperate with,  but independently from, the industry. This has been achieved by not allowing any registry to be sponsored by one company only but by allowing sponsorship of the entire project for 3 years. This has also allowed us to conduct the special registries which will never attract sponsorship and two of these have been presented today. One on cardiomyopathy and another one on cardiovascular disease in pregnancy;
  • To involve the CBs. All the registries are run by NCSs, Associations and WGs;
  • To cooperate with  European authorities and we have started to do so with EMA, the Organisation for Economic Co-operation and Development (OECD).

ESC TV: Watch Prof. Ferrari's interview

We are proud to announce that, in total, 70.000 patients have been involved so far. 

Carlo Di Mario (UK). The Main results of the TAVI part of the Transcatheter Valve Treatment refers to 4571 consecutive patient.  Overall, 3.1 % of the population presented Major vascular complication, 13.2% of the patients were implanted with pacemakers, 1.8% underwent a stroke and 7.4 died. A sub analyses on anesthesia included 1095 in the local anesthesia/conscious sedation group and 1712 patients in the general anesthesia group. The difference in in-hospital mortality between Local anesthesia (7%) and General anaesthesia (5.3%) was statistically different (p = 0.053). The analyses of the mitraclip component of the registry included 628 patients Results from the NYHA evaluation showed a clear improvement of the patients conditions in all classes with significant reduction of mitral regurgitation

Peter Ludman (UK) – The pilot phase of the Acute Coronary Syndrome in STEMI patients is currently being launched by the ESC through its registry programme (EORP). We hope that this registry will ssupport improved treatment of STEMI across Europe and provide audit tools to help drive up quality of care. The pilot phase of this registry is scheduled to be set in 13 homogenously distributed countries in Europe with an aim of recruiting 3 000 patients from proportional ratio of interventional to non-interventional centres for each country before enlarging it to many more ESC country members.

Perry Elliot (UK) – The recruitment of the pilot phase of the Cardiomyopathy registry is now complete and 1115 patients recruited across 12 European countries. Results confirmed the expected distribution of types of cardiomyopathies with a prevalence showed in our registry of 61%, 31%, 5% and 3%  prevalence of HCM, DCM, ARVC and RCM respectively. Familial disease, genetic counseling and testing in the majority of the cases, a heavily medicated cohort using evidence based treatment and a very high prevalence of ICDs, particularly in ARVC

Roger Hall (UK) – The recruitment of the ROPAC registry on pregnancy and Cardiac Disease is steadily increasing with the participation of 50 countries, 77 centres and over 3600 pregnant women included across the world. 5000 patients are targeted to be enrolled. The goals of this registry is to assess risks for both mother and child, outline variation between different geographic regions, test and validate risk models and develop future guideline. The conclusion of the intermediate analysis showed an increased maternal and fetal mortality overall, an individual risks increased for mother and child in cardiomyopathy, prosthetic valves and anticoagulant therapies. More data will be needed to draw more meaningful conclusions.

David Wood (UK) – The exciting EuroAspire IV project enrolled 8000 coronary patients in 26 countries. Results have showed that about two thirds (66.3%) of coronary patients have dysglycaemia (IFG, IGT), undetected diabetes or self reported diabetes mellitus. The main conclusions drawn from this first phase were that all patients with coronary disease should be formally investigated for dysglycaemia and diabetes by an OGTT and managed accordingly to reduce the risk of micro-vascular and macro-vascular disease.




ESC registries, Organised by EURObservational Research Programme

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.